Prils Market Players:
- Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Boehringer Ingelheim International GmbH
- Sun Pharmaceuticals Industries Ltd.
- Pfizer Inc.
- Mylan N.V
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Manus Aktteva Biopharma LLP
- Canagen Pharmaceuticals Inc.
- Lupin Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of prils is evaluated at USD 2.65 billion.
The global prils market size was worth more than USD 2.51 billion in 2025 and is poised to witness a CAGR of over 6.4%, crossing USD 4.67 billion revenue by 2035.
North America is anticipated to command a 41% share of the Prils Market by 2035, owing to the increasing cases of obesity.
Key players in the market include Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited.
